MECHELEN, BELGIUM--(Marketwire - Mar 8, 2013) -
* COPD alliance signed in December 2009 and broadened to fibrosis in
* Strategic change in therapy area at Roche resulted in conclusion of the
* Galapagos regains full rights to all programs
* Roche pays Galapagos EUR5.75 M for work completed in 2012
Galapagos NV (EURONEXT BRUSSELS: GLPG) announced today
that it agreed with Roche to end their alliance in fibrosis. Roche will
payment of EUR5.75 million to Galapagos for work completed in 2012,
to 2012 Group revenues.
With the ending of the alliance, Galapagos has regained the worldwide
all fibrosis assays and the targets discovered in the alliance. These
targets were identified in various unique human primary cell assays
fibrosis. Galapagos will have received a total of EUR16 million in
milestone payments, including this latest payment.
"We regret that Roche ended the alliance due to a strategic change, but the
news is that all assets have returned to Galapagos," said Onno van de
CEO of Galapagos. "Our plan is to find another partner to continue the
for compounds against these debilitating diseases."
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
with a large pipeline of four clinical, six pre-clinical, and 30
small-molecule and antibody programs in cystic fibrosis,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
of rheumatoid arthritis and potentially other inflammatory diseases,
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide
agreement whereby AbbVie will be responsible for further
commercialization after Phase 2b. Galapagos has another selective
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly
in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin
antagonist currently in a Phase 1b patient study in metastasis. GLPG0974
first inhibitor of GPR43 to be evaluated clinically for the treatment of
this program will start a Proof of Concept Phase 2 study in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus,
Fidelta, has over 800 employees and operates facilities in five countries,
global headquarters in Mechelen, Belgium. Further information at:
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
Galapagos and Roche conclude strategic alliance:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE